Acute Mesenteric Ischemia
17
6
6
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 17 trials
100.0%
+13.5% vs benchmark
6%
1 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (17)
Assessment of Quality of Life After Acute Mesenteric Ischemia
Searching Biomarkers of Acute Intestinal Ischemic Injuries
Evaluation of the Discriminative Abilities of Biomarkers for the Diagnosis of Acute Mesenteric Ischemia Compared With Another Similar Clinical Presentation: a Pilot Study
Perioperatively Assessed Biomarker I-FABP Level for Prediction of Acute Mesenteric Ischemia and Its Correlation With Acute Kidney Injury, Followed by Extracorporeal Circulation (aMIKI)
Performance of the SeptiCyte LAB Test for Antibiotic Stewardship in Mesenteric Ischemia
The Feasibility of a Radiological Score Based on CT Signs for Recognizing Salvageable Bowel in Acute Mesenteric Ischemia
ORal Antibiotics in Acute Mesenteric Ischemia
Biomarkers in Prediction of AMI
Acute Mesenteric Ischemia, Reality in Catalonia
Analysis of the Acute Mesenteric Ischemia in a Single Institution Over 10 Years
Antithrombotic Management of Acute Mesenteric Ischaemia
Incidence, Diagnosis, Management and Outcome of Acute Mesenteric Ischemia
Acute Intestinal Necrosis- the Preoperative Diagnostic Approach
Epidemiology of Acute Mesenteric Ischemia
The Detrimental Course of Acute Intestinal Ischemia
Mesenteric Ischemia in the Emergency Department: a Retrospective Multicenter Study
Plasma i-FABP as Predictor for Irreversible Bowel Ischemia